| Literature DB >> 30379953 |
Jesús Mateos1, Juan Fafián-Labora1, Miriam Morente-López1, Iván Lesende-Rodriguez2, Lorenzo Monserrat2, María A Ódena3, Eliandre de Oliveira3, Javier de Toro1, María C Arufe1.
Abstract
Hutchinson-Gilford progeria syndrome (HGPS) is a very rare fatal disease characterized for accelerated aging. Although the causal agent, a point mutation in LMNA gene, was identified more than a decade ago, the molecular mechanisms underlying HGPS are still not fully understood and, currently, there is no cure for the patients, which die at a mean age of thirteen. With the aim of unraveling non-previously altered molecular pathways in the premature aging process, human cell lines from HGPS patients and from healthy parental controls were studied in parallel using Next-Generation Sequencing (RNAseq) and High-Resolution Quantitative Proteomics (iTRAQ) techniques. After selection of significant proteins and transcripts and crosschecking of the results a small set of protein/transcript pairs were chosen for validation. One of those proteins, ribose-phosphate pyrophosphokinase 1 (PRPS1), is essential for nucleotide synthesis. PRPS1 loss-of-function mutants present lower levels of purine. PRPS1 protein and transcript levels are detected as significantly decreased in HGPS cell lines vs. healthy parental controls. This modulation was orthogonally confirmed by targeted techniques in cell lines and also in an animal model of Progeria, the ZMPSTE24 knock-out mouse. In addition, functional experiments through supplementation with S-adenosyl-methionine (SAMe), a metabolite that is an alternative source of purine, were done. Results indicate that SAMe has a positive effect in the proliferative capacity and reduces senescence-associated Beta-galactosidase staining of the HPGS cell lines. Altogether, our data suggests that nucleotide and, specifically, purine-metabolism, are altered in premature aging, opening a new window for the therapeutic treatment of the disease.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30379953 PMCID: PMC6209416 DOI: 10.1371/journal.pone.0205878
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Parallel genomic and proteomic workflows.
Schematic representation of the workflow followed for the genomic (left) and proteomic (right) large-scale approaches. HGPS and Healthy Progenitor cell lines were processed for RNA and total protein isolation. RNA was converted to cDNA for analysis in a Illumina Hi seq 1500 platform. Two technical replicates were analyzed for each sample. Raw data was processed and statistical analysis was done using Bowtie2, TopHat and Cufflinks programs. Total protein extracts were labeled using iTRAQ 8-plex. Two biological replicates were processed in parallel (iTRAQ1 and iTRAQ2). Labelled peptides were fractionated by Basic Reversed-phase chromatography and fractions were analyzed in a LTQ-Orbitrap Velos platform. Protein quantification was done using Proteome Discoverer 2.1 software and XLSTAT software was used for statistical analysis.
Fig 2Transcripts and proteins significantly modulated in HGPS-derived cells versus healthy parental control cell lines.
Volcano plot representations of the RNAseq (A) and shotgun proteomics (B) analysis of the HGPS and Control cell lines. For RNAseq, a threshold of q-value = 0.05 was set for significance according the statistical package used for analysis. A total of 911 transcripts present a q-value ≤ 0.05. For shotgun proteomics a threshold of p-value = 0.001 was set for significance according to the statistical package used. In this case 219 proteins were detected as significant with a p-value ≤ 0.001.
Fig 3Crosschecking of the genomic and proteomic results shows that HGPS present features of a metabolic disorder.
Representation of the modulation in HGPS versus Control cell lines of the transcripts detected as significant and those correlating with the proteomic approach (red dots in A). String 10.4 gene ontology statistical study of the 22 transcript/protein coincident pairs (B, C, D) demonstrate that most of the proteins are membrane-bounded or secreted and have a role on glycolysis, energy generation and synthesis of bio-molecules.
Crosschecking of the RNAsec and ITRAQ data.
| Gene name | Protein name | RNAsec data: Up in | iTRAQ data: Up in | Function |
|---|---|---|---|---|
| AHNAK2 | Protein AHNAK2 | Control | Control | Regulation of calcium channels. |
| ANPEP | Aminopeptidase N | Control | Control | Digestion of proteins. |
| BAG2 | BAG family molecular chaperone regulator 2 | Control | Control | Protein folding. |
| CAPG | Macrophage-capping protein | Control | Control | Cytoplasmic and nuclear structure. |
| CCDC80 | Coiled-coil domain-containing protein 80 | Control | Control | Extracellular matrix organization. |
| COL12A1 | Collagen alpha-1(XII) chain | Control | Control | Extracellular matrix organization. |
| COL4A2 | Collagen alpha-2(IV) chain | HGPS | HGPS | Extracellular matrix organization. |
| CSPG4 | Chondroitin sulfate proteoglycan 4 | HGPS | HGPS | Regulation of cell proliferation and migration |
| ENO2 | Gamma-enolase | HGPS | HGPS | Glycolysis. |
| EPHX1 | Epoxide hydrolase 1 | Control | Control | Catabolism of aromatic compounds. |
| GPNMB | Transmembrane glycoprotein NMB | HGPS | Control | Cell migration and adhesion. |
| ISG15 | Ubiquitin-like protein ISG15 | HGPS | HGPS | Defense against bacteria. |
| ITGA3 | Integrin alpha-3 | HGPS | HGPS | Cell adhesion and cell-cell interaction. |
| MYH10 | Myosin-10 | Control | Control | Cell shape and cytokynesis. |
| NES | Nestin | HGPS | HGPS | Intermediate fillament binding. |
| P4HA2 | Prolyl 4-hydroxylase subunit alpha-2 | Control | HGPS | Proline hydroxilation in collagen. |
| PFKP | ATP-dependent 6-phosphofructokinase | HGPS | HGPS | Glycolysis. |
| PRPS1 | Ribose-phosphate pyrophosphokinase 1 | Control | Control | Nucleotide biosynthesis. |
| PSME2 | Proteasome activator complex subunit 2 | HGPS | HGPS | Proteosomal degradation. |
| RAD23B | UV excision repair protein RAD23 homolog B | Control | Control | Proteosomal degradation, part of the XPC complex. |
| S100A16 | Protein S100-A16 | Control | Control | Calcium binding protein, adipocyte differentiation. |
| THY1 | Thy-1 membrane glycoprotein | Control | Control | Cell adhesion and cell-cell interaction. |
| TNC | Tenascin | Control | Control | Extracellular matrix organization. |
| UACA | Uveal autoantigen with coiled-coil domains and ankyrin repeats | HGPS | HGPS | Regulation of stress-induced apoptosis. |
List of the 24 protein/transcript pairs selected after the crosschecking of the proteomics and transcriptomics data.
Fig 4Targeted validation of PRPS1 shows down-regulation of transcript and protein levels in HGPS-cells and the animal model of HPGS, respectively.
Orthogonal validation of PRPS1 modulation by targeted techniques in cell lines (A, B) and in the mouse model of HGPS (C, D). Real-Time PCR (RT-PCR) of HGPS and control cell lines (A) showing that PRPS1 transcript is down-regulated in the three HGPS cell lines when compare to their respective controls. Statistical analysis (B) demonstrates that the difference between control and HGPS is significant (p-value ≤ 0.01). Representative images (C) of the immunohystochemistry of the PRPS1 protein in liver sections of the ZMPSTE24-null mice strain (magnification: 20x). Statistical analysis shows that wild-type mice (WT) present significant (p-value ≤ 0.05) higher levels of the protein than heterozygous and null mice.
Fig 5An alternative source of purine partially reverts the premature phenotype aging in HGPS-derived cells.
Effect of incubation with SAMe on the premature-aging phenotype of HGPS cell lines. MTT-based proliferation assay (A) showing that periodic addition of SAMe to the culture media at a final concentration of 10 μg/mL, have a significant (p-value≤ 0.05) positive effect in the proliferation capacity of two out of the three cell lines after 10 days in culture. Representative images (magnification: 20x) of the staining of Senescence Associated Beta-galactosidase (SA-β-gal) staining in HGPS cells with and without SAMe addition to the culture media (B), showing a higher number of negative cells (arrows) in SAMe-treated cells. Densitometry analysis of the staining signal shows a decrease in two of the HGPS cell lines after incubation with SAMe (C).
Fig 6Proposed model to explain the down-regulation of PRPS1 in HGPS.
Enzymes in blue are detected as down-regulated and those in red as up-regulated in the present study. High glycolitic rate in HGPS drives to a decrease in the levels of D-Ribose-5-phosphate available for de novo purine synthesis. This reduction compromises PRPS1 activity. Furthermore, this inhibition is complemented by free amino-acid starvation resulting from down-regulation of ANPEP. As a result, de novo nucleotide synthesis is affected thus promoting defects in key biological processes that contribute to the premature aging phenotype. Supplementation of SAMe helps to restore the levels of AMP which, in turn, could be transformed to GMP by the cellular machinery, partially ameliorating the premature aging phenotype. Abbreviations: PFKP: ATP-dependent 6-phosphofructokinase; ENO2: gamma-enolase; PRPS1: ribose-phosphate pyrophosphokinase 1; ANPEP: aminopeptidase N; GPAT: glutamine-phosphorybosil aminotransferase; GARS: glycinamide-ribonucleotide synthetase; GART: glycinamide-ribonucleotide transformylase; IMP: inosine monophosphate; GMP: guanosine monophosphate; AMP: adenosine monophosphate; SAMe: S-adenosylmethionine; SAH: S-adenosylhomocysteine; AHCY: S-adenosylhomocysteine hydrolase.